Dimerix Limited (AU:DXB) has released an update.
Dimerix Limited, a biopharmaceutical company focused on therapies for unmet medical needs, successfully passed all resolutions at its Annual General Meeting on October 1, 2024. Key decisions included the re-election and election of directors, approval of a 10% placement capacity, and the ratification of issued shares and options to related parties. The resolutions reflect the company’s commitment to strategic growth and governance as it advances its Phase 3 clinical asset in kidney disease.
For further insights into AU:DXB stock, check out TipRanks’ Stock Analysis page.